Cotinga Pharmaceuticals Ár/Könyv
Mi az Cotinga Pharmaceuticals Ár/Könyv?
A Ár/Könyv az Cotinga Pharmaceuticals, Inc. - -116.24
Mi a Ár/Könyv meghatározása?
Az ár-könyv arány aránya a vállalat részvényértéke és az egy részvényre jutó könyv szerinti érték arányát jelenti.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Ár/Könyv a Health Care szektor a TSXV-on cégekben a Cotinga Pharmaceuticals -hoz képest
Mit csinál Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
ár/könyv -hoz hasonló cégek Cotinga Pharmaceuticals
- Black Iron nak Ár/Könyv -120.34 van
- HCA Healthcare nak Ár/Könyv -120.12 van
- Huntsman Exploration Inc nak Ár/Könyv -118.25 van
- Regeneus Ltd nak Ár/Könyv -117.67 van
- Changsheng International nak Ár/Könyv -117.65 van
- Sable Resources nak Ár/Könyv -117.24 van
- Cotinga Pharmaceuticals nak Ár/Könyv -116.24 van
- Astra nak Ár/Könyv -113.97 van
- A2Z Technologies Canada nak Ár/Könyv -112.65 van
- Taiga Motors nak Ár/Könyv -112.18 van
- Clean Power Hydrogen Plc nak Ár/Könyv -108.51 van
- Fabled Copper nak Ár/Könyv -105.66 van
- Astra Exploration Inc nak Ár/Könyv -102.83 van